Progress in the etiology and pathogenesis research of chronic inflammatory bowel disease;FORTSCHRITTE IN DER ATIOLOGIE-UND PATHOGENESEFORSCHUNG DER CHRONISCH ENTZUNDLICHEN DARMERKRANKUNGEN

Internist

Volumn 39, Issue 10, 1998, Pages 1004-1012

  Dignass, A ^a,b   Goebell, H ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CYTOKINE; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 4; SOMATOMEDIN C; TUMOR NECROSIS FACTOR ALPHA;

CROHN DISEASE; ENTERITIS; HELICOBACTER PYLORI; HUMAN; IMMUNE STATUS; MEMBRANE PERMEABILITY; MUCOSA INFLAMMATION; PATHOGENESIS; REVIEW; ULCERATIVE COLITIS;

CYTOKINES; HUMANS; INFLAMMATORY BOWEL DISEASES; INTESTINAL MUCOSA; LYMPHOCYTE SUBSETS;

EID: 0031727887     PISSN: 00209554     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001080050271     Document Type: Review

References (56)

1. Bayless TM, Tokayer AZ, Polito JM, Quaskey SA, Mellits ED, Harris ML (1996) Crohn's disease: concordance for site and clinical type in affected family members-potential hereditary influences. Gastroenterol 111: 573-579
2. Colgan SP, Parkos CA, Matthews JB, D'Andrea L, Awtrey CS, Lichtman AH, Delp-Archer C, Madara JL (1994) Interferon-gamma induces a cell surface phenotype switch on T84 intestinal epithelial cells. Am J Physiol 267: C402-C410
3. Colombel JF, Grandbastien B, Gower-Rousseau C, Plegat S, Evrard JP, Dupas JL, Gendre JP, Modigliani R, Belaiche J, Hostein J, Hugot JP, van Kruiningen H, Cortot A (1996) Clinical characteristics of Crohn's disease in 72 families. Gastroenterol 111: 604-607
4. Conner EM, Brand SJ, Davis JM, Grisham MB (1996) Role of reactive metabolites of oxygen and nitrogen in inflammatory bowel disease: toxins, mediators, and modulators of gene expression. Inflammatory Bowel Dis 2: 133-147
5. Duchmann R, Kaiser I, Hermann E, Mayet W, Ewe K, Meyer zum Buschenfelde KH (1995) Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD). Clin Exp Immunol 102: 448-455
6. Duchmann R, Schmitt E, Knolle P, Meyer zum Buschenfelde KH, Neurath M (1996) Tolerance towards resident intestinal flora in mice is abrogated in experimental colitis and restored by treatment with interleukin-10 or antibodies to interleukin-12. Eur J Immunol 26: 934-938
7. Ekbom A, Daszak P, Kraaz W, Wakefield AJ (1996) Crohn's disease after in-utero measles virus exposure. Lancet 348: 515-517
8. Elson CO, Sartor RB, Tennyson GS, Riddell RH (1995) Experimental models of inflammatory bowel disease. Gastroenterol 109: 1344-1367
9. Gilberts EC, Greenstein AJ, Katsel P, Harpaz N, Greenstein RJ (1994) Molecular evidence for two forms of Crohn disease. Proc Natl Acad Sci USA 91: 12721-12724
10. Haga Y, Funakoshi O, Kuroe K, Kanazawa K, Nakajima H, Saito H, Murata Y, Munakata A, Yoshida Y (1996) Absence of measles viral genomic sequence in intestinal tissues from Crohn's disease by nested polymerase chain reaction. Gut 38: 211-215
11. Hermiston ML, Gordon JI (1995) Inflammatory bowel disease and adenomas in mice expressing a dominant negative N-cadherin. Science 270: 1203-1207
12. Hugot JP, Laurent-Puig P, Gower-Rousseau C, Olson JM, Lee JC, Beaugerie L, Naom I, Dupas JL, Van Gossum A, Orholm M, Bonaiti-Pellie C, Weissenbach J, Mathew CG, Lennard-Jones JE, Cortot A, Colombel JF, Thomas G (1996) Mapping of a susceptibility locus for Crohn's disease on chromosome 16. Nature 379: 821-823
13. Jewell DP (1995) Immunology of inflammatory bowel disease - an update. J Gastroenterol 30 Suppl 8: 78-82
14. Katschinski B (1993) Smoking and ovulation inhibitor in inflammatory bowel diseases. Med Klin 88 [Suppl 1]: 5-8
15. Katz KD, Hollander D, Vadheim CM, McElree C, Delahunty T, Dadufalza VD, Krugliak P, Rotter JI (1989) Intestinal permeability in patients with Crohn's disease and their healthy relatives. Gastroenterol 97: 927-931
16. Koutroubakis I, Manousos ON, Meuwissen SG, Pena AS (1996) Environmental risk factors in inflammatory bowel disease. Hepatogastroenterology 43: 381-393
17. Kuhn R, Lohler J, Rennick D, Rajewsky K, Müller W (1993) IL-10 deficient mice develop chronic enterocolitis. Cell 75: 263-274
18. Liu Y, Van Kruiningen HJ, West AB, Cartun RW, Cortot A, Colombel JF (1995) Immunocytochemical evidence of Listeria, Escherichia coli, and Streptococcus antigens in Crohn's disease. Gastroenterol 108: 1396-1404
19. MacDermott RP (1996) Alterations of the mucosal immune system in inflammatory bowel disease. J Gastroenterol 31: 907-916
20. MacDermott RP, Sanderson IR, Reinecker HC (1998) The central role of chemokines (chemotactic cytokines) in the immunopathogenesis of ulcerative colitis and Crohn's disease. Inflammm Bowel Dis 4: 54-67
21. Madara JL, Stafford J (1989) Interferon-gamma directly affects barrier function of cultured intestinal epithelial monolayers. J Clin Invest 83: 724-727
22. Mansfield JC, Holden H, Tarlow JK, Di Giovine FS, McDowell TL, Wilson AG, Holdsworth CD, Duff GW (1994) Novel genetic association between ulcerative colitis and the anti-inflammatory cytokine interleukin-1 receptor antagonist. Gastroenterol 106: 637-642
23. Mashimo H, Wu D-C, Podolsky DK, Fishman MC (1996) Impaired defense of intestinal mucosa in mice lacking intestinal trefoil factor. Science 274: 262-265
24. May GR, Sutherland LR, Meddings JB (1993) Is small intestinal permeability really increased in patients with Crohn's disease? Gastroenterol 104: 1627-1632
25. Mayer L, Eisenhardt D (1990) Lack of induction of suppressor T cells by intestinal epithelial cells from patients with inflammatory bowel disease. J Clin Invest 86: 1255-1260
26. Mullin GE, Maycon ZR, Braun-Elwert L, James SP (1996) Inflammatory bowel disease mucosal biopsies have specialized lymphokine mRNA profiles. Inflammatory Bowel Dis 2: 16-26
27. Munkholm P, Langholz E, Hollander D, Thornberg K, Orholm M, Katz KD, Binder V (1994) Intestinal permeability in patients with Crohn's disease and ulcerative colitis and their first degree relatives. Gut 35: 68-72
28. Neurath MF, Fuss I, Kelsall BL, Presky DH, Waegell W, Strober W (1996) Experimental granulomatous colitis in mice is abrogated by induction of TGF-beta-mediated oral tolerance. J ExpMed 183: 2605-2616
29. Neurath MF, Fuss I, Kelsall BL, Stuber E, Strober W (1995) Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med 182: 1281-1290
30. Pena AS, Crusius JBA (1998) Genetics of inflammatory bowel disease: Implications for the future. World J Surg 22: 390-393
31. Plevy SE, Targan SR, Yang H, Fernandez D, Rotter JI, Toyoda H (1996) Tumor necrosis factor microsatellites define a Crohn's disease- associated haplotype on chromosome 6. Gastroenterol 110: 1053-1060
32. Podolsky DK, Isselbacher KJ (1984) Glycoprotein composition of colonic mucosa. Specific alterations in ulcerative colitis. Gastroenterol 87: 991-998
33. Rath HC, Herfarth HH, Ikeda JS, Grenther WB, Hamm TE Jr, Balish E, Taurog JD, Hammer RE, Wilson KH, Sartor RB (1996) Normal luminal bacteria, especially Bacteroides species, mediate chronic colitis, gastritis, and arthritis in HLA-B27/human beta2 microglobulin transgenic rats. J Clin Invest 98: 945-953
34. Rhodes JM (1989) Colonic mucus and mucosal glycoproteins: the key to colitis and cancer? Gut 30: 1660-1666
35. Rogler G, Andus T (1998) Cytokines in inflammatory bowel disease. World J Surg 22: 382-389
36. Sadlack B, Merz H, Schorle H, Schimpl A, Feller AC, Horak I (1993) Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell 75: 253-261
37. Sandborn WJ, Tremaine WJ, Offord KP, Lawson GM, Petersen BT, Batts KP, Croghan IT, Dale LC, Schroeder DR, Hurt RD (1997) Transdermal nicotine for mildly to moderately active ulcerative colitis. A randomized, double-blind, placebo-controlled trial. Annals of Internal Medicine 126: 364-371
38. Sanderson JD, Moss MT, Tizard ML, Hermon-Taylor J (1992) Mycobacterium paratuberculosis DNA in Crohn's disease tissue. Gut 33: 890-896
39. Sartor RB (1994) Cytokines in intestinal inflammation: pathophysiological and clinical considerations. Gastroenterol 106: 533-539
40. Sartor RB (1995) Current concepts of the etiology and pathogenesis of ulcerative colitis and Crohn's disease. Gastroenterol Clin North Am 24: 475-507
41. Sartor RB (1996) Cytokine regulation of experimental intestinal inflammation in genetically engineered and T-lymphocyte reconstituted rodents. Aliment Pharmacol Ther 10 Suppl 2: 36-42
42. Sartor RB (1997) Pathogenesis and immune mechanisms of chronic inflammatory bowel diseases. Am J Gastroenterol 92: 5S-11S
43. Satsangi J, Jewell DP, Bell JI (1997) The genetics of inflammatory bowel disease. Gut 40: 572-574
44. Satsangi J, Parkes M, Louis E, Hashimoto L, Kato N, Welsh K, Terwilliger JD, Lathrop GM, Bell JI, Jewell DP (1996) Two stage genome-wide search in inflammatory bowel disease provides evidence for susceptibility loci on chromosomes 3, 7 and 12. Nat Genet 14: 199-202
45. Satsangi J, Welsh KI, Bunce M, Julier C, Farrant JM, Bell JI, Jewell DP (1996) Contribution of genes of the major histocompatibility complex to susceptibility and disease phenotype in inflammatory bowel disease. Lancet 347: 1212-1217
46. Schreiber S, Stange EF (1997) Morbus Crohn und Colitis ulcerosa - Neue Erkenntnisse zur Immunpathogenese. Dtsch Ärztebl 94: 1268-1274
47. Shanahan F (1994) Current concepts of the pathogenesis of inflammatory bowel disease. Ir J Med Sci 163: 544-549
48. Shull MK, Ormsby I, Kier AB (1992) Targeted disruption of the mouse transforming growth factor β1 gene results in multifocal inflammatory disease. Nature 359: 693-699
49. Thomas GA, Rhodes J, Green JT (1998) Inflammatory bowel disease and smoking -a review. Am J Gastroenterol 93: 144-149
50. Thomas GA, Swift GL, Green JT, Newcombe RG, Braniff-Mathews C, Rhodes J, Wilkinson S, Strohmeyer G, Kreuzpainter G (1998) Controlled trial of antituberculous chemotherapy in Crohn's disease: a five year follow up study. Gut 42: 497-500
51. van Deventer SJ, Elson CO, Fedorak RN (1997) Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Crohn's Disease Study Group. Gastroenterol 113: 383-389
52. van Dullemen HM, van Deventer SJ, Hommes DW, Bijl HA, Jansen J, Tytgat GN, Woody J (1995) Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterol 109: 129-135
53. Wakefield AJ, Ekbom A, Dhillon AP, Pittilo RM, Pounder RE (1995) Crohn's disease: pathogenesis and persistent measles virus infection. Gastroenterol 108: 911-916
54. Yacyshyn BR, Bowen-Yacyshyn MB, Jewell L, Tami JA, Bennett CF, Kisner DL, Shanahan WR Jr (1998) A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease. Gastroenterol 114: 1133-1142
55. Yang H, Rotter JI (1994) Genetics of inflammatory bowel disease. In:Targan SR, Shanahan F (eds) Inflammatory bowel disease: from bench to bedside. Williams & Wilkins, Baltimore, Philadelphia, Hong Kong, pp 32-64
56. Yang H, Vora DK, Targan SR, Toyoda H, Beaudet AL, Rotter JI (1995) Intercellular adhesion molecule 1 gene associations with immunologic subsets of inflammatory bowel disease. Gastroenterol 109: 440-448